Tesamorelin Case Study: Body Recomposition, IGF-1, Metabolic Health and Longevity
- Aug 24
- 8 min read
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it stimulates the body's own pituitary release of growth hormone, subsequently influencing IGF-1 (insulin-like growth factor 1).
Tesamorelin is best known clinically for its use in reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. However, the relationship between growth hormone, IGF-1, body composition, metabolic health and longevity is considerably more complicated than simply assuming that higher or lower IGF-1 is always better.
In these two case studies, we followed two males using Tesamorelin peptides in the UK, combining body-composition observations with longitudinal biomarkers measured through TruHealth by TruDiagnostic.
The two participants started from quite different positions: one was already very lean, while the other described himself as "skinny fat." Interestingly, both demonstrated signs of body recomposition without conventional weight loss.
Case Study 1 – 37-Year-Old Male
The first participant was a 37-year-old male who was already relatively lean before beginning Tesamorelin.
Because there was relatively little excess body fat to lose, dramatic changes on the scales were neither expected nor necessarily desirable.
Nevertheless, his before-and-after photographs showed an improvement in body composition while his overall body weight remained approximately the same.
This is a useful example of why body weight alone can be a poor measurement of a successful recomp. A person can lose fat while simultaneously maintaining or gaining lean tissue, resulting in very little change in total weight despite a noticeable change in appearance and body composition.
IGF-1
His epigenetically measured IGF-1 increased from:
24th percentile → 39th percentile
This represents a meaningful upward shift in the IGF-1 signal during the intervention and is directionally consistent with the expected biological action of Tesamorelin through the growth hormone/IGF-1 axis.
Glucose and HbA1c
One consideration when increasing growth hormone and IGF-1 signalling is glucose regulation.
Interestingly, this participant's metabolic biomarkers moved in a favourable direction.
His epigenetic measurements showed:
HbA1c: improved by 5 percentile points
Glucose: improved by 6 percentile points
The epigenetic glucose measurement should not be interpreted in exactly the same way as a conventional fasting glucose blood test.
A serum glucose test provides a snapshot of glucose at that particular moment. By contrast, an epigenetic glucose-associated signal can provide information reflecting longer-term patterns of glucose exposure rather than simply what happened on the morning of the test.
In practical terms, it can therefore provide complementary information to traditional glucose and HbA1c measurements when following metabolic health over time.
It is important, however, not to attribute the improvement entirely to Tesamorelin.
The participant was simultaneously using alpha-lipoic acid and berberine phytosome, a formulation designed to improve berberine bioavailability. Both could potentially have contributed to the favourable metabolic changes.
The more conservative conclusion is therefore that his IGF-1 increased substantially without an accompanying deterioration in the measured glucose-related biomarkers. In fact, both moved in a favourable direction during the same period.
Case Study 2 – 49-Year-Old Male
The second participant was a 49-year-old male who described his starting physique as "skinny fat."
His baseline weight was approximately 71 kg. Consequently, losing large amounts of body weight wasn't necessarily the objective. Improving body composition – particularly reducing abdominal fat while preserving lean tissue – was considerably more relevant.
At the end of the intervention:
Body weight: +0.5 kg
Waist circumference: -0.75 inches
This is an interesting result.
If scale weight had been the only measurement used, the intervention could actually have appeared unsuccessful because he gained approximately half a kilogram.
However, his waist became three-quarters of an inch smaller.
Although waist circumference cannot distinguish visceral from subcutaneous abdominal fat, a smaller waist alongside stable or increased body weight is consistent with a favourable change in body composition and potentially an improvement in the ratio of fat mass to lean mass.
IGF-1
His TruHealth results showed epigenetically measured IGF-1 increasing from:
33rd percentile → 42nd percentile
Again, the direction of change was consistent with increased activity of the growth hormone/IGF-1 pathway, although his response was somewhat smaller than that observed in the 37-year-old participant.
HbA1c
His epigenetic HbA1c changed from:
54th percentile → 56th percentile
This was a relatively small movement, but it is important to include neutral or unfavourable findings rather than selectively reporting only positive outcomes.
This participant was using dihydroberberine, whereas the younger participant used berberine phytosome alongside alpha-lipoic acid.
The metabolic-support strategies were therefore different, making direct comparisons between the two participants difficult.
Why Measure IGF-1 Epigenetically?
One of the particularly useful aspects of these case studies was the ability to look at IGF-1 from a longer-term epigenetic perspective.
A conventional serum IGF-1 blood test remains extremely valuable, particularly when assessing the current circulating concentration and ensuring that an intervention is not pushing IGF-1 excessively high.
However, biological markers fluctuate.
Sleep, nutrition, training load, recovery status, illness and other physiological factors can influence the growth hormone/IGF-1 axis. A single blood measurement therefore provides valuable information, but it is still a measurement taken at one particular point in time.
When trying to establish whether somebody genuinely has relatively low IGF-1, repeated conventional measurements can therefore be useful rather than relying entirely on one result.
This is particularly relevant before considering any intervention affecting the growth hormone pathway, including growth hormone treatment or growth hormone secretagogues.
Traditionally, obtaining two or three measurements at different points can provide greater confidence that a low result represents an underlying pattern rather than short-term biological variation.
Epigenetics Provides a Different Perspective
An epigenetic measurement can complement this approach by providing a longer-term biological signal.
Rather than replacing serum IGF-1 testing, the two approaches can potentially be used together.
Think of them as answering slightly different questions:
Serum IGF-1:"Where is my circulating IGF-1 now?"
Epigenetic IGF-1:"What longer-term pattern is my biology showing?"
This can be especially useful when monitoring interventions over several months.
A conventional blood test can help identify whether IGF-1 is becoming excessively elevated in the short term, while longitudinal epigenetic testing can help determine whether the overall trajectory has shifted.
IGF-1 and Longevity: Higher Isn't Necessarily Better
When discussing Tesamorelin, growth hormone or peptides affecting the GH/IGF-1 pathway, it is important not to present increasing IGF-1 as an objective in itself.
From a longevity perspective, more is not necessarily better.
IGF-1 plays an important role in tissue repair, muscle maintenance, recovery and anabolic signalling. However, persistently excessive growth signalling may also increase cellular proliferation and turnover – one reason chronically elevated IGF-1 is of interest when considering cancer risk and longevity.
At the opposite extreme, extremely low IGF-1 is not necessarily desirable either.
As we age, maintaining muscle mass, strength and physical resilience becomes increasingly important. Very low anabolic signalling can contribute to poor recovery, loss of lean tissue and frailty.
For somebody exercising frequently or intensely, inadequate recovery alongside very low IGF-1 may also create its own problems.
This creates something of a longevity trade-off.
The objective is not necessarily to maximise IGF-1 or minimise it. Instead, a more sensible longevity-oriented approach may be to maintain sufficient anabolic signalling to support muscle, recovery and metabolic health without chronically driving growth signalling excessively high.
The "Goldilocks" Approach to IGF-1
This is where longitudinal testing becomes particularly useful.
Within the TruHealth framework, we generally view approximately the 50th percentile for age as a useful reference point when thinking from a longevity-biased perspective, rather than deliberately trying to push IGF-1 towards the upper end of the distribution.
That should not be interpreted as a universally established clinical treatment target. It is better considered a longevity-oriented reference point for interpreting these particular results.
The aim is essentially a Goldilocks zone:
Not excessively low. Not excessively high.
For the participants in these case studies, IGF-1 moved:
37-year-old: 24th → 39th percentile49-year-old: 33rd → 42nd percentile
Both therefore moved closer towards the middle of their age-adjusted distribution rather than being pushed towards an extreme.
The Potential Trade-Off: IGF-1 vs Visceral Fat
There is another important longevity question raised by these results.
What happens if an intervention temporarily increases IGF-1 but simultaneously improves body composition and reduces abdominal or visceral adiposity?
This isn't necessarily a simple good-versus-bad equation.
Chronically excessive IGF-1 may be undesirable from a longevity perspective because of its relationship with growth signalling and cellular proliferation.
However, carrying excessive visceral fat for years or decades has its own consequences.
Visceral adipose tissue is metabolically active and is associated with insulin resistance, cardiovascular risk and chronic metabolic dysfunction.
Consequently, there is a reasonable longevity discussion around whether a temporary, controlled increase in IGF-1 could represent an acceptable trade-off if it facilitates a meaningful and sustained improvement in body composition and metabolic health.
For example, somebody carrying excessive abdominal fat for decades may potentially gain considerably from reducing that burden, even if an intervention produces a temporary increase in growth signalling.
That does not mean that higher IGF-1 becomes harmless simply because somebody is losing fat.
It instead demonstrates why these interventions should be viewed in context.
The objective would be to avoid unnecessarily high or chronically elevated IGF-1 while simultaneously considering the potential health benefits associated with improved body composition, reduced abdominal adiposity and better metabolic health.
What Do These Two Tesamorelin Case Studies Tell Us?
These are two individual observational case studies, so they cannot establish causality.
However, there were several interesting similarities.
Both participants experienced an increase in epigenetically measured IGF-1:
24th → 39th percentile
and
33rd → 42nd percentile
Both also demonstrated evidence consistent with body recomposition without conventional weight loss.
The already-lean 37-year-old remained approximately the same weight while becoming visibly leaner.
The 49-year-old gained approximately 0.5 kg while losing 0.75 inches from his waist.
The metabolic results were more individual.
The younger participant's epigenetic HbA1c and glucose improved by five and six percentile points respectively, while the older participant's HbA1c increased slightly from the 54th to 56th percentile.
Because both individuals were using additional glucose-support interventions, these changes cannot confidently be attributed to Tesamorelin itself.
That is precisely why case studies like these become more useful when photographs, body weight, waist circumference and longitudinal biomarkers are considered together rather than focusing on one measurement.
Tesamorelin, TruDiagnostic UK and Long-Term Monitoring
For those researching Tesamorelin in the UK, these case studies demonstrate the potential value of combining conventional testing with longitudinal epigenetic measurements.
TruHealth by TruDiagnostic can provide another layer of information when investigating longer-term changes in IGF-1 and metabolic health, while conventional blood testing remains valuable for assessing current circulating levels.
Neither should necessarily be considered a replacement for the other.
For growth hormone-related interventions in particular, combining the two approaches can provide a more complete picture: a current snapshot alongside a longer-term biological trend.
From a health and longevity perspective, the objective should not simply be to produce the largest possible increase in IGF-1.
The more interesting question is whether body composition and metabolic health can be improved while maintaining the growth hormone/IGF-1 axis within a sensible range.
These two cases provide an interesting early example of that balance.
Research Disclaimer
These case studies are observational and are presented for educational and research purposes only. They do not demonstrate that Tesamorelin caused the changes described and should not be interpreted as medical advice or evidence of efficacy or safety. Tesamorelin is a prescription medicine in some jurisdictions, and interventions affecting the growth hormone/IGF-1 axis warrant appropriate clinical oversight and monitoring.
The clients featured in these case studies purchased their UK research peptides through Elvian Labs, selected due to the availability of recent independent product testing alongside periodic sterility testing.
Multiple interventions were used during these case studies, including berberine derivatives and alpha-lipoic acid, meaning changes in metabolic biomarkers cannot be attributed to Tesamorelin in isolation.
Comments